Evaluation of antibiotic prescribing patterns in patients receiving sustained low-efficiency dialysis: Opportunities for pharmacists

International Journal of Pharmacy Practice

Volumn 21, Issue 1, 2013, Pages 55-61

  Harris, Laura E ^a   Reaves, Anne B ^a   Krauss, Amy G ^a   Griner, Justin ^b   Hudson, Joanna Q ^b  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

antibiotic dosing; drug clearance; kidney failure; prescribing practices; sustained low efficiency dialysis

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; DORIPENEM; GENTAMICIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SUSTAINED LOW EFFICIENCY DIALYSIS;

ANTI-BACTERIAL AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL ROLE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TENNESSEE;

EID: 84872254198     PISSN: 09617671     EISSN: 20427174     Source Type: Journal    
DOI: 10.1111/j.2042-7174.2012.00226.x     Document Type: Article

References (26)

1. Heintz BH, et al. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29: 562-577.
2. Bogard KN, et al. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 2011; 39: 560-570.
3. Lam YW, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32: 30-57.
4. Ghannoum M, et al. Blood purification in toxicology: nephrology's ugly duckling. Adv Chronic Kidney Dis 2011; 18: 160-166.
5. Deshpande P, et al. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). Nephrol Dial Transplant 2010; 25: 2632-2636.
6. Mushatt DM, et al. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009; 49: 433-437.
7. Kielstein JT, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2010; 25: 1537-1541.
8. Fiaccadori E, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32: 2437-2442.
9. Kielstein JT, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34: 51-56.
10. Mueller SC, et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002; 46: 1557-1560.
11. Trotman RL, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-1166.
12. Choi G, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37: 2268-2282.
13. Swoboda S, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66: 291-298.
14. Burkhardt O, et al. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008; 61: 224-225.
15. Anon,. Cubicin (Daptomycin) [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc., 2010.
16. Isla A, et al. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005; 27: 599-608.
17. Cirillo I, et al. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. Antimicrob Agents Chemother 2011; 55: 1187-1193.
18. Hidaka S, et al. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakugaku Zasshi 2010; 130: 87-94.
19. Hashimoto S, et al. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ASAIO J 1997; 43: 84-88.
20. Kihara M, et al. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. Clin Nephrol 1994; 42: 193-197.
21. Fish DN, et al. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005; 49: 2421-2428.
22. Anon,. Doribax [package insert]. Raritan, NJ: Ortho-McNeil-Hanssen Pharmaceuticals, Inc., 2007.
23. Anon,. Primaxin [package insert]. Whitehouse Station, NJ: Merck and Company, Inc., 2010.
24. Amin NB, et al. Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. Am J Kidney Dis 1999; 34: 222-227.
25. Manley HJ, et al. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int 2003; 63: 1072-1078.
26. Sowinski KM, et al. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 2008; 3: 355-361.